AcquisitionsMay 5, 2026, 04:34 PM
Alkermes Completes $2.31B Avadel Acquisition; Q1 Net Loss $(66.5)M
AI Summary
Alkermes plc completed the acquisition of Avadel Pharmaceuticals plc for $2.31 billion on February 12, 2026, significantly impacting its financial position. The company reported a net loss of $(66.5) million for Q1 2026, a decline from a net income of $22.5 million in Q1 2025, primarily due to acquisition-related expenses and increased interest costs. Despite the loss, total revenues grew 28.2% to $392.9 million, driven by a 38.3% increase in product sales. The acquisition led to a substantial increase in total assets to $4.26 billion and total liabilities to $2.51 billion, including $1.48 billion in long-term debt.
Key Highlights
- Alkermes completed the acquisition of Avadel Pharmaceuticals for $2.31 billion on February 12, 2026.
- Q1 2026 net loss was $(66.5) million, compared to $22.5 million net income in Q1 2025.
- Total revenues increased 28.2% to $392.9 million in Q1 2026 from $306.5 million year-over-year.
- Product sales, net, rose 38.3% to $338.1 million in Q1 2026.
- Total assets increased to $4.26 billion from $2.49 billion at December 31, 2025.
- Total liabilities surged to $2.51 billion from $667.7 million at December 31, 2025.
- Operating activities used $165.7 million cash in Q1 2026 vs. $98.8 million provided in Q1 2025.
- Long-term debt increased to $1.48 billion from zero at December 31, 2025.